Abstract:
There are several different retinal diseases prominent within the United
States including
age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma.
These three particular retinal diseases affect a total of 12.5 million people
in the US alone, showing that retinal diseases are a very prevalent issue
that require an improvement in the methodology of treatment. Retinal diseases
can cause blindness and drastically decrease quality of life. To better treat
these diseases and provide patients with proper care, it is important to
maintain a proper understanding of the retina.
It has been found that retinal organoids (ROs) can be produced through the
use of stem cells. When perfected, these ROs can provide advanced modeling of
the retina, as well as modeling of novel treatments for retinal diseases and
allow for better testing. Additionally, ROs can be modified in order to
better depict retinal diseases and their microenvironments. They may also be
used for retinal transplants as a method of treatment. However, ROs are still
being developed and understood. Before the full use and benefits of ROs can
be reaped, the differences between ROs and natural retinas must be understood
and minimized. Additionally, various issues within the ROs themself must be
tackled in order for their uses to become more advanced.